VistaGen Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTGN research report →
About the company
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder.
- CEO
- Shawn K. Singh
- IPO
- 2011
- Employees
- 48
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $8.16M
- P/E
- -0.13
- P/S
- 6.42
- P/B
- 0.27
- EV/EBITDA
- 0.31
- Div Yield
- 0.00%
- Gross Margin
- 71.81%
- Op Margin
- -5678.74%
- Net Margin
- -5487.01%
- ROE
- -133.02%
- ROIC
- -197.24%
- Revenue
- $1.27M · 161.11%
- Net Income
- $-69,685,000 · -35.53%
- EPS
- $-1.83 · -9.58%
- Op Income
- $-72,126,000
- FCF YoY
- -57.10%
- 52W High
- $5.14
- 52W Low
- $0.20
- 50D MA
- $0.59
- 200D MA
- $1.71
- Beta
- 0.40
- Avg Volume
- 1.97M
Get TickerSpark's AI analysis on VTGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Adler Reid G. | other | 36,818 |
| Jun 30, 26 | Tressler Nick B. | other | 11,712 |
| Jun 30, 26 | Singh Shawn | other | 36,818 |
| May 18, 26 | Angelov Angel S | other | 150,000 |
| May 18, 26 | Angelov Angel S | other | 0 |
| Apr 7, 26 | Tressler Nick B. | other | 75,000 |
| Apr 7, 26 | Singh Shawn | other | 71,268 |
| Apr 7, 26 | Singh Shawn | other | 3,732 |
| Apr 7, 26 | Prince Joshua S. | other | 56,248 |
| Apr 7, 26 | Prince Joshua S. | other | 18,752 |
Our VTGN coverage
Recent articles, reports, and earnings notes.
No research on VTGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VTGN report →Similar companies
Peers in the same neighborhood.